MS4A2 and melanoma: From the metabolic regulation perspective, MS4A2 modulates the tumor immune microenvironment through mast cell activity, with its high correlation to resting mast cells (r = 0.58) suggesting predictive potential for immunotherapy response - analogous to mast cell markers in melanoma [62] and aligning with discoveries on metabolic reprogramming in CAR-T efficacy [63].